News
Our science
Aiming for safer,
more accessible
genome editing technology
Breeding, or "crossbreeding," has been practiced since ancient times, but the discovery of "genome editing technology," especially the CRISPR-Cas9 system discovered in 2012, has brought revolutionary technological innovation due to its simplicity and speed.
With the Nobel Prize in Chemistry to be awarded in 2020 and the approval of a new gene therapy utilizing Cas9 technology in 2023, expectations for genome editing technology are rising.
Under these circumstances, CRISPR-Cas3, invented by Professor Tomoji Mashimo and his group, is a novel technology from Japan that opens up new possibilities for genome editing by making it safer and more widely applicable.




Our Business
Creating a Sustainable
Society by Implementing
CRISPR-Cas3 in the industry
Based on cutting-edge research,
CRISPR-Cas3 is being applied as a platform technology not only for medical applications,
but also for a wide range of industrial applications.

Pipeline
C4U is pursuing research and development of new therapies through its own pipeline and partner pipelines.







Partnership
To exploit the broad application potential of the CRISPR-Cas3 technology, C4U is engaged in various collaborations and licensing activities.